375 related articles for article (PubMed ID: 11181775)
1. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
Harro CD; Pang YY; Roden RB; Hildesheim A; Wang Z; Reynolds MJ; Mast TC; Robinson R; Murphy BR; Karron RA; Dillner J; Schiller JT; Lowy DR
J Natl Cancer Inst; 2001 Feb; 93(4):284-92. PubMed ID: 11181775
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.
Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E
Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427
[TBL] [Abstract][Full Text] [Related]
3. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women.
Fife KH; Wheeler CM; Koutsky LA; Barr E; Brown DR; Schiff MA; Kiviat NB; Jansen KU; Barber H; Smith JF; Tadesse A; Giacoletti K; Smith PR; Suhr G; Johnson DA
Vaccine; 2004 Jul; 22(21-22):2943-52. PubMed ID: 15246631
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
[TBL] [Abstract][Full Text] [Related]
5. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
[TBL] [Abstract][Full Text] [Related]
6. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.
Safaeian M; Porras C; Pan Y; Kreimer A; Schiller JT; Gonzalez P; Lowy DR; Wacholder S; Schiffman M; Rodriguez AC; Herrero R; Kemp T; Shelton G; Quint W; van Doorn LJ; Hildesheim A; Pinto LA;
Cancer Prev Res (Phila); 2013 Nov; 6(11):1242-50. PubMed ID: 24189371
[TBL] [Abstract][Full Text] [Related]
7. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.
Mao C; Koutsky LA; Ault KA; Wheeler CM; Brown DR; Wiley DJ; Alvarez FB; Bautista OM; Jansen KU; Barr E
Obstet Gynecol; 2006 Jan; 107(1):18-27. PubMed ID: 16394035
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
Robbins HA; Waterboer T; Porras C; Kemp TJ; Pawlita M; Rodriguez AC; Wacholder S; Gonzalez P; Schiller JT; Lowy DR; Esser M; Matys K; Poncelet S; Herrero R; Hildesheim A; Pinto LA; Safaeian M
Hum Vaccin Immunother; 2014; 10(10):2965-74. PubMed ID: 25483632
[TBL] [Abstract][Full Text] [Related]
10. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
[TBL] [Abstract][Full Text] [Related]
11. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
Giannini SL; Hanon E; Moris P; Van Mechelen M; Morel S; Dessy F; Fourneau MA; Colau B; Suzich J; Losonksy G; Martin MT; Dubin G; Wettendorff MA
Vaccine; 2006 Aug; 24(33-34):5937-49. PubMed ID: 16828940
[TBL] [Abstract][Full Text] [Related]
12. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation.
Park MH; You JW; Kim HJ; Kim HJ
J Microbiol; 2019 Sep; 57(9):821-827. PubMed ID: 31452045
[TBL] [Abstract][Full Text] [Related]
13. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E
Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048
[TBL] [Abstract][Full Text] [Related]
14. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
Park JS; Oh YK; Kang MJ; Kim CK
J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.
Ballou WR; Reed JL; Noble W; Young NS; Koenig S
J Infect Dis; 2003 Feb; 187(4):675-8. PubMed ID: 12599085
[TBL] [Abstract][Full Text] [Related]
16. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
17. A human papillomavirus type 16 vaccine by oral delivery of L1 protein.
Sasagawa T; Tani M; Basha W; Rose RC; Tohda H; Giga-Hama Y; Azar KK; Yasuda H; Sakai A; Inoue M
Virus Res; 2005 Jun; 110(1-2):81-90. PubMed ID: 15845258
[TBL] [Abstract][Full Text] [Related]
18. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine.
Emeny RT; Wheeler CM; Jansen KU; Hunt WC; Fu TM; Smith JF; MacMullen S; Esser MT; Paliard X
J Virol; 2002 Aug; 76(15):7832-42. PubMed ID: 12097595
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.
Arévalo MT; Huang Y; Jones CA; Ross TM
PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007316. PubMed ID: 31026260
[TBL] [Abstract][Full Text] [Related]
20. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions.
Balmelli C; Roden R; Potts A; Schiller J; De Grandi P; Nardelli-Haefliger D
J Virol; 1998 Oct; 72(10):8220-9. PubMed ID: 9733865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
